FDA approves device for improving prostate biopsies
The FDA has approved TargetScan, a new device for conducting prostate biopsies.
The FDA has approved TargetScan, a new device for conducting prostate biopsies. The device combines 3-D image acquisition with a stationary probe to help physicians plan and execute targeted prostate biopsies, potentially improving patients' cancer treatment outcomes with less-invasive procedures, according to its manufacturer, Envisioneering Medical Technologies, St. Louis.
"We've learned that current diagnostic tools are inadequate-missing cancer in some patients while over testing others," said Gerald Andriole, MD, of Washington University School of Medicine, St. Louis, and a member of the Envisioneering medical advisory board. "With TargetScan, we anticipate improved cancer detection-saving time, money and possibly lives."
The device also plays a role in prostate cancer treatment. It eliminates the need to physically move the probe, so the prostate position will be stabilized during radioactive seed implantation.
TargetScan is currently available in select U.S. urology clinics for field testing. A widespread launch is planned in conjunction with the AUA annual meeting in May.
From evidence to practice: Dr. Makarov discusses implementation science in urology
July 25th 2024“What our major contribution is, I think as urologists doing implementation science, is determining the important questions, which we are particularly well-suited to do because we're taking care of the patients,” says Danil V. Makarov, MD, MHS.
